[1] | Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 65(1): p. 5-29. |
|
[2] | Ludwig, H., et al., International Myeloma Working Group recommendations for global myeloma care. Leukemia, 2014. 28(5): p. 981-92. |
|
[3] | Palumbo, A. and K. Anderson, Multiple myeloma. N Engl J Med, 2011. 364(11): p. 1046-60. |
|
[4] | Adams, J. and M. Kauffman, Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest, 2004. 22(2): p. 304-11. |
|
[5] | Siegel, D.S., et al., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 2012. 120(14): p. 2817-25. |
|
[6] | Dimopoulos, M.A., et al., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol, 2016. 17(1): p. 27-38. |
|
[7] | Chari, A. and D. Hajje, Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer, 2014. 14: p. 915. |
|
[8] | Harvey, R.D., Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol, 2014. 6: p. 87-96. |
|
[9] | Hobeika, L., S.E. Self, and J.C. Velez, Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol, 2014. 15: p. 156. |
|
[10] | Noris, M. and G. Remuzzi, Atypical hemolytic-uremic syndrome. N Engl J Med, 2009. 361(17): p. 1676-87. |
|
[11] | Noris, M., et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010. 5(10): p. 1844-59. |
|
[12] | Roy, V., et al., Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant, 2001. 27(6): p. 641-6. |
|
[13] | Besbas, N., et al., A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int, 2006. 70(3): p. 423-31. |
|
[14] | Eremina, V., et al., VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med, 2008. 358(11): p. 1129-36. |
|
[15] | Reese, J.A., et al., Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol, 2015. 90(5): p. 406-10. |
|
[16] | Al-Nouri, Z.L., et al., Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015. 125(4): p. 616-8. |
|
[17] | Moore, H. and K. Romeril, Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J, 2011. 41(4): p. 348-50. |
|
[18] | Eremina, V. and S.E. Quaggin, Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol, 2010. 30(6): p. 582-90. |
|
[19] | Usui, J., et al., Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol, 2014. 45(9): p. 1918-27. |
|
[20] | Yui, J.C., et al., Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol, 2016. 91(9): p. E348-52. |
|
[21] | Chan, K.L., et al., Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymphoma, 2015. 56(7): p. 2185-6. |
|
[22] | Mehta, N., A. Saxena, and R. Niesvizky, Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep, 2012. 2012. |
|
[23] | Salmenniemi, U. and K. Remes, Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep, 2012. 4(2): p. e13. |
|
[24] | Morita, R., et al., Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol, 2008. 88(2): p. 248-250. |
|
[25] | Lodhi, A., et al., Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J, 2015. 8(5): p. 632-6. |
|
[26] | Sullivan, M.R., et al., Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher, 2015. 30(5): p. 308-10. |
|
[27] | Qaqish, I., et al., Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci, 2016. 54(3): p. 401-4. |
|
[28] | Gosain, R., et al., Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep, 2017. 5(12): p. 1926-1930. |
|
[29] | Chen, Y., et al., Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer Journal, 2016. 6: p. e450. |
|
[30] | Atrash, S., et al., Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM). Blood, 2012. 120(21): p. 5037-5037. |
|
[31] | Van Keer, J., et al., Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma. Case Rep Hematol, 2016. 2016: p. 6020691. |
|
[32] | Yui, J.C., A. Dispenzieri, and N. Leung, Ixazomib-induced thrombotic microangiopathy. Am J Hematol, 2017. 92(4): p. E53-e55. |
|
[33] | Atallah-Yunes, S.A. and M.H. Soe, Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib. Case Rep Hematol, 2018. 2018: p. 7063145. |
|
[34] | Legendre, C.M., et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med, 2013. 368(23): p. 2169-81. |
|
[35] | Stewart, A.K., et al., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med, 2015. 372(2): p. 142-52. |
|